{"id":"W2947026438","doi":"10.1200/jco.2019.37.15_suppl.6000","title":"Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Cetuximab; Carboplatin; Population; Head and neck squamous-cell carcinoma; Pembrolizumab; Internal medicine; Interim analysis; Cisplatin; Oncology; Head and neck cancer; Urology; Nuclear medicine; Radiation therapy; Randomized controlled trial; Surgery; Cancer; Chemotherapy; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009899746,0.002398758,0.002308109,0.0004963112,0.0009522081,0.001644558,0.001626921,0.002217014,0.02124749],"category_scores_gemma":[0.006844193,0.001076082,0.002444591,0.0005728045,0.0008962486,0.0009875153,0.0007026801,0.003886416,0.004618917],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001831562,"about_ca_system_score_gemma":0.004870361,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008665489,"about_ca_topic_score_gemma":0.002365891,"domain_scores_codex":[0.9963866,0.002482021,0.0001821228,0.0003234101,0.0002577612,0.000368072],"domain_scores_gemma":[0.9975713,0.0004976749,0.0004874115,0.0004005035,0.0003887392,0.0006543232],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9417663,0.004841335,0.001255104,0.001176721,0.001670314,0.0001744502,0.00009238131,0.001329418,0.005833147,0.0007653175,0.0212671,0.01982837],"study_design_scores_gemma":[0.9154358,0.05167613,0.00495442,0.0001592486,0.001043806,0.0001300226,0.00002947954,0.001303615,0.00226203,0.001131138,0.02183142,0.00004280604],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"protocol","genre_gemma":"empirical","genre_scores_codex":[0.2770624,0.004289778,0.01498496,0.003775188,0.002617746,0.5997638,0.06312141,0.0009450778,0.03343967],"genre_scores_gemma":[0.4131954,0.001412502,0.01905278,0.005221118,0.0004199526,0.5146182,0.03104012,0.0002335458,0.01480637],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.02124749,"threshold_uncertainty_score":0.07107991,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1809768907209643,"score_gpt":0.4906753055908003,"score_spread":0.309698414869836,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}